JERSEY CITY, N.J., Oct. 19, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Rare Kidney Diseases Market By Target Indications (IgA Nephropathy, Membranous Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Focal Segmental Glomerular Sclerosis, and Others), Type of Molecule (Small Molecules and Biologics (Hormone, Monoclonal Antibody, Recombinant Protein, and Others)), Route of Administration (Intravenous, Oral, Subcutaneous, and Others))- Market Outlook and Industry Analysis 2030" According to company's newest research, the global rare kidney diseases market is predicted to exhibit a promising CAGR of 16% between 2022 and 2030.
Rare kidney diseases (RKD) encompass approximately 150 distinct conditions. In the United States (US) and Europe, the prevalence of rare kidney diseases is estimated to range between 60 and 80 per 100,000 cases/individuals. Approximately one-third of adults with diabetes and one-fifth of adults with hypertension may have kidney disease. Kidney diseases kill more people than breast and prostate cancers combined (NVS 2021 report of 2018 data). Kidney disease patients are five to ten times more probable to die prematurely than to develop kidney failure with replacement therapy (KFRT). It's important to note that after the COVID-19 pandemic started, it became even harder to treat people with rare kidney diseases. This is mainly because most current treatments for these conditions require patients to go to the hospital or medical center often. As a result, the death rate for sick people during the pandemic went up by 30%. This rise in death rates has forced people in the pharmaceutical industry to do the research they need to find new drugs that can effectively treat rare kidney diseases.
Get a Demo Sample copy of the Report at https://www.insightaceanalytic.com/request-sample/1414
Several essential factors are driving the growth of the market for rare kidney diseases. The collaborative interactions among clinicians, patients, industry representatives, regulatory agents, and government agencies contribute to the expansion of the need for complex illnesses due to new advancements in diagnosis and treatment. In addition, the increased use of next-generation sequencing techniques is expected to improve diagnostic accuracy for rare kidney diseases, aid in elucidating molecular mechanisms of disease, facilitate genetic counselling, and provide opportunities for carrier testing. Renal replacement therapy advancements and increased accessibility enable patients to live longer lives at the expense of their quality of life.
The market restraining factors include unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and obsolete diagnostic classifications that do not reflect underlying pathophysiological mechanisms, which have hindered therapeutic advances in rare kidney diseases. Slow drug approvals and complex studies will also restrain the market's growth.
North America will dominate and lead the global market for rare kidney diseases during the forecasted period as a result of its rapid clinical advancements and research into kidney disease treatments.
The key market players are GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1414
Key Developments in The Market:
- In Aug 2022, CSL Vifor and Travere Therapeutics announced that the European Medicines Agency (EMA) has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of a rare kidney disorder IgAN, and a leading cause of end-stage kidney disease (ESKD).
- In Dec 2021, The FDA approved the first drug to reduce urine protein levels in IgA nephropathy, a rare kidney disease. Tarpeyo (budesonide) delayed-release capsules have been granted accelerated approval by the FDA to minimise proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression.
- In Sept 2021, Allarity Therapeutics and Lonza agreed to collaborate on developing and manufacturing dovitinib, Allarity's renal cell carcinoma candidate therapy. The agreement called for the start of dovitinib manufacturing in 2022 to meet Allarity's projected needs for bringing dovitinib to market after regulatory approvals.
- In June 2021, Novartis announced new Phase II interim data for iptacopan in the rare kidney disease C3 glomerulopathy (C3G). Iptacopan is being developed for a number of (CDRDs) complement-driven renal diseases, including C3Gand (IgAN) IgA nephropathy, the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), with the goal of addressing a vital driver of these diseases.
Market Segmentation
Global Rare Kidney Diseases Market, by Target Indication, 2022-2030 (Value US$ Mn)
- IgA Nephropathy
- Lupus Nephritis
- Focal Segmental Glomerular Sclerosis
- Membranous Nephropathy
- C3 Glomerulopathy
- Cystinosis
- Dense Deposit Disease
- Distal Renal Tubular Acidosis
- Fabry Disease
- Refractory Gout
- Atypical Hemolytic Uremic Syndrome
- Others
Global Rare Kidney Diseases Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
- Small Molecules
- Biologics
- Monoclonal Antibody
- Hormone
- Recombinant Protein
- Others
Global Rare Kidney Diseases Market, by Route of Administration, 2022-2030 (Value US$ Mn)
- Oral
- Intravenous
- Subcutaneous
- Others
Global Rare Kidney Diseases Market, by Region, 2022-2030 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
- U.S.
- Canada
Europe Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
For Customization: https://www.insightaceanalytic.com/customisation/1414
Other Related Reports Published by InsightAce Analytic:
Global Biosimilar Monoclonal Antibodies Market
Global Dialysis Equipment Market
Global Therapeutic Proteins and Oral Vaccines Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rare-kidney-diseases-market-to-is-projected-to-grow-at-a-cagr-of-16-during-the-period-2022-2030-claims-insightace-analytic-301653600.html
